This session offers a timely, forward-looking discussion on FDA activities and their potential impact on FSIS-regulated products and operations. With ongoing developments expected, the session will focus on key areas of regulatory attention, including GRAS determinations and broader ingredient oversight considerations. 

The session will begin with a high-level overview of emerging FDA priorities and areas to watch. It will then transition into a series of rapid, focused updates from ingredient suppliers, each providing insight into how regulatory shifts may influence product formulation, approvals, and compliance strategies. 

Designed as a concise, high-impact session, the format combines expert perspective with practical industry input to help attendees stay ahead of evolving expectations and understand how FDA actions may shape FSIS environments. 

This session is intended for those looking to anticipate change, assess risk, and adapt formulation and compliance strategies in a shifting regulatory landscape.